title: Clinical, molecular, and genomic changes in response to a left ventricular assist device.
abstract: The use of left ventricular assist devices in treating patients with end-stage heart failure has increased significantly in recent years, both as a bridge to transplantation and as destination therapy in those who are ineligible for cardiac transplantation. This increase is based largely on the results of several recently completed clinical trials with the new second-generation continuous-flow devices that showed significant improvements in survival, functional capacity, and quality of life. Additional information on the use of the first- and second-generation left ventricular assist devices has come from a recently released report spanning the years 2006 to 2009, from the Interagency Registry for Mechanically Assisted Circulatory Support, a National Heart, Lung, and Blood Institute-sponsored collaboration between the U.S. Food and Drug Administration, the Centers for Medicare and Medicaid Services, and the scientific community. The authors review the latest clinical trials and data from the registry, with tight integration of the landmark molecular, cellular, and genomic research that accompanies the reverse remodeling of the human heart in response to a left ventricular assist device and functional recovery that has been reported in a subset of these patients.
authors.affiliation: Division of Cardiology, Department of Medicine, University of Minnesota, Minneapolis, 55455, USA. jlhall@umn.edu
authors.forename: Jennifer L
authors.initials: JL
authors.lastname: Hall
authors.forename: David R
authors.initials: DR
authors.lastname: Fermin
authors.forename: Emma J
authors.initials: EJ
authors.lastname: Birks
authors.forename: Paul J R
authors.initials: PJ
authors.lastname: Barton
authors.forename: Mark
authors.initials: M
authors.lastname: Slaughter
authors.forename: Peter
authors.initials: P
authors.lastname: Eckman
authors.forename: Hideo A
authors.initials: HA
authors.lastname: Baba
authors.forename: Jeremias
authors.initials: J
authors.lastname: Wohlschlaeger
authors.forename: Leslie W
authors.initials: LW
authors.lastname: Miller
mesh_terms: D000818:Animals; D002118:Calcium / Q000378:metabolism; D053379:Chromogranin A / Q000378:metabolism; D002986:Clinical Trials as Topic; D003598:Cytoskeletal Proteins / Q000378:metabolism; D015870:Gene Expression; D006333:Heart Failure / Q000378:metabolism / Q000628:therapy*; D006353:Heart-Assist Devices; D006801:Humans; D035683:MicroRNAs / Q000378:metabolism; D009200:Myocardial Contraction; D032383:Myocytes, Cardiac / Q000502:physiology; D045265:Natriuretic Peptides / Q000378:metabolism; D011943:Receptors, Adrenergic, beta / Q000378:metabolism; D020127:Recovery of Function; D015398:Signal Transduction
chemical_list: D053379:Chromogranin A; D003598:Cytoskeletal Proteins; D035683:MicroRNAs; D045265:Natriuretic Peptides; D011943:Receptors, Adrenergic, beta; D002118:Calcium